Equities research analysts forecast that Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Rating) will report earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tyra Biosciences’ earnings. The company is expected to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Tyra Biosciences will report full-year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.28) to ($1.05). For the next year, analysts expect that the business will post earnings of ($1.54) per share, with EPS estimates ranging from ($1.73) to ($1.40). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Tyra Biosciences.
Tyra Biosciences (NASDAQ:TYRA – Get Rating) last announced its earnings results on Thursday, March 3rd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03).
A number of hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new position in shares of Tyra Biosciences during the 1st quarter valued at about $113,000. BlackRock Inc. acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at about $8,281,000. Wells Fargo & Company MN acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at about $99,000. TCG Crossover Management LLC acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at about $11,966,000. Finally, Deutsche Bank AG acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at about $104,000. 99.96% of the stock is currently owned by institutional investors.
Shares of NASDAQ TYRA opened at $8.19 on Tuesday. Tyra Biosciences has a 12 month low of $6.25 and a 12 month high of $31.36. The business has a fifty day simple moving average of $10.13 and a 200-day simple moving average of $14.44.
Tyra Biosciences Company Profile (Get Rating)
Tyra Biosciences, Inc, a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
- Get a free copy of the StockNews.com research report on Tyra Biosciences (TYRA)
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Time to Buy These 3 Oversold Mid-Caps
- Institutional Support For Tyson Foods Is Growing
- Johnson Outdoors Falls On Bleak Outlook
- Littelfuse Stock is Hitting on All Cylinders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.